Clarivate Acquires Patient Connect, Furthering Position as a Leading Provider of Patient-Centric Solutions
Expanded global offerings allow life science companies to make confident, data-driven decisions tailored to their patient populations LONDON, Dec. 22, 2021 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced that it has acquired Patient Connect, a provider of patient engagement...
Technology central to sustainability, affordability of global healthcare industry
SINGAPORE, Dec. 21, 2021 /PRNewswire/ -- Healthcare spending saw a steep decline during the COVID-19 pandemic with associated lockdowns, restrictions, and postponement of non-essential treatments. However, the trend is expected to be short-lived as COVID-19 vaccines and testing became widely available, and healthcare usage begins to rebound. "Almost every year, and with very little exception, healthcare spending grows faster than...
TCM provides new alternatives for the fight against COVID-19
BEIJING, Dec. 22, 2021 /PRNewswire/ -- A news report by haiwainet.cn: During the 18th World Congress of Traditional Chinese Medicine held on 4 December 2021, experts from Spain, France, Australia and other countries and regions highly recognized the role of Traditional Chinese Medicine (TCM) in fighting against COVID-19. Dr. Chen Zhen, President of the Central and Eastern European Federation...
Karyopharm and Menarini Group Enter into Exclusive License Agreement to Commercialize NEXPOVIO® (selinexor) in Europe and Other Key Global Territories
- Menarini Group Obtains Exclusive Rights to Commercialize NEXPOVIO for the Treatment of Hematologic and Solid Tumor Oncology Indications in Europe (including the United Kingdom), Latin America and Other Key Countries - Karyopharm to Receive $75 Million Upfront, then Eligible to Receive Up to $202.5 Million in Future Milestones, Plus Tiered,...
World Health Organization SAGE Issues Interim Recommendations for Novavax COVID-19 Vaccine
- WHO Strategic Advisory Group of Experts on Immunization (SAGE) recommends primary two-dose vaccination series of NVX-CoV2373 in persons aged 18 and older - SAGE recommends additional third dose of NVX-CoV2373 administered to immunocompromised persons - Recommendation follows grant of WHO Emergency Use Listing for Novavax' vaccine GAITHERSBURG, Md., Dec. 22,...
Ortoma Signs Agreement for Exclusive Distribution Rights in Japan
STOCKHOLM, Dec. 22, 2021 /PRNewswire/ -- Ortoma signs agreement with Johnson & Johnson K.K. for exclusive distribution rights in Japan of the Ortoma Treatment Solution for hip surgery. It is the first agreement that the company executes with a global strategic partner. The agreement allows for the possibility to expand the partnership to other global markets. Ortoma is...
EVERSANA completes acquisition of Intouch Group, adds the premiere digital-first agency network to the market leader in next generation commercialization
CHICAGO and KANSAS CITY, Mo., Dec. 21, 2021 /PRNewswire/ -- EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, today announced it has completed its acquisition of Intouch Group®, a full-service global agency network serving the pharmaceutical industry. The acquisition immediately propels EVERSANA's position as a $1...
Jolly Good develops a medical VR filming system exclusively for ambulances with physicians
TOKYO, Dec. 21, 2021 /PRNewswire/ -- Jolly Good Inc. ("Jolly Good") developed a medical VR filming system for ambulances with physicians in collaboration with Nippon Medical School Hospital Emergency & Critical Care Medicine (Bunkyo-ku, Tokyo; Director: Shoji Yokobori). Together, they will begin testing the usability of this VR system in the field of critical care medicine. Jolly...
Novaliq Announces POSITIVE Topline Results for SECOND PHASE 3 TRIAL (ESSENCE-2) of CyclASol® in Dry Eye Disease
HEIDELBERG, Germany and CAMBRIDGE, Mass, Dec. 21, 2021 /PRNewswire/ -- Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced key results of the second pivotal Phase 3 trial (ESSENCE-2) evaluating the investigational drug CyclASol® for the treatment of dry eye disease...
Hanjiao Group Invited by Rising China Interview Show
BEIJING, Dec. 21, 2021 /PRNewswire/ -- Hanjiao Group, Inc. ("Hanjiao" or the "Company") (OTC Pink: HJGP), a Nevada holding corporation that, through its variable interest entity, is engaged in providing home care services and related healthcare products to the middle-aged and elderly communities in the PRC through its online e-Commerce platform and offline service centers, today announced the...
